A: The model changes from country to country. Do you want to beat the performance of the current Gold Standard? Do you have to be cheaper than the competition? Innovex Consulting now has considerable experience in most therapeutic areas in major markets as well as in developing markets, and we’d be happy to advise.

A: An alternative to the traditional sales models, Innovex teams of Clinical Educators and Nurse Advisers share information with physicians that helps them improve patient outcomes for disease states that are frequently under-diagnosed, misdiagnosed, or under-treated.

Additionally, they MAY have the ability to reach out directly to patients and help them understand why it’s so important to take their medicine exactly as prescribed.

A: The effectiveness of your sales teams can vary from one region to another for seemingly no reason. Frequently, the answer lies in the effectiveness of the coaching techniques deployed by different managers. The award winning Innovex Innsight™ compares different management techniques, the results they achieve, and identifies best practices in representative evaluation and coaching.

A: As you know, getting domestic and international key opinion leaders talking and writing about your drug can hasten its approval and give it market momentum.

Innovex Medical Communications has vast experience and techniques from publication planning to STRATEGIC SEMIOTICS TM to engage the people that matter.

A: Regulations continue to evolve as they come under pressure from politicians and the payer community alike. Our continuing experience across all markets and therapies means we have an up-to-date picture of local conditions for anyone about to launch an important new drug.

A: This is a problem that faces many smaller pharmaceutical and biotech businesses that simply don’t have the in-house resources to plan, execute and manage the commercialization of their discoveries.

Now you can tap into our end-to-end commercialization solution without needing to manage dozens of different suppliers or, worse still, failing to optimize potential shareholder value by having to out-license.

A: Traditionally, the methodology has been to use research to find out what messages have been delivered successfully and been effective, but this often suffers from poor audience recall.

Innovex Call Performance Analysis, extensively used in the UK, enables your sales force and marketers to test their messages on real prescribers prior to launch to identify what will be most effective in a simulated real-life situation.

A: Differences in employment law can make it almost impossible to downsize a sales force in one country. Rapidly mobilizing a team in another country presents a different type of challenge. Achieving both at the same time can be extremely complex. The only way to retain true flexibility is to change the sales force model, across your portfolio, and introduce an appropriate level of outsourcing.

A: The market drivers for payers, regulators and subscribers are completely different for many niche products, but especially so for new personalized medicines. Without an in-depth knowledge of the issues that concern these stakeholders you risk lengthening launch timescales and negatively affecting your potential returns.

A: As we all know, the skills required to sell to a specialist or consultant are entirely different from those required to sell to a General Practitioner or physician.

Advances in targeted recruiting based on behavioral science has proven results in the selection and fielding of higher performing representatives.

Additional Innovex research into the motivators of specialist representatives, and their training needs to be effective with the specialist physician audience, has put Innovex at the forefront of the specialty care market.